The Latest Breaking News from Goldman Sachs

To keep doing business with Texas, companies will effectively have to take a vow of neutrality if the latest school-shooting massacre sets off another nationwide furor over gun control.

Upgrades Credit Suisse upgraded the previous rating for Molecular Partners AG (NASDAQ:MOLN) from Underperform to Neutral. NoneAt the moment, the stock has a 52-week-high of $32.04 and a 52-week-low of $5.92. Molecular Partners closed at $6.88 at the end of the last trading period.

Goldman Sachs has decided to maintain its Buy rating of Apellis Pharmaceuticals (NASDAQ:APLS) and lower its price target from $94.00 to $84.00. Shares of Apellis Pharmaceuticals are trading down 2.3% over the last 24 hours, at $43.40 per share.

NEW YORK — The cold-blooded Manhattan subway killer who shot a Goldman Sachs researcher at random was captured on video giving the murder weapon to a homeless man who quickly sold the gun, police sources said Monday.

Fatal attacks on public transport continue to be rare but that offers little comfort to Adams as he struggles to establish his mayoralty

Goldman Sachs economists slashed U.S. growth forecasts and warned of potential recession risks earlier this month, citing uncertainty surrounding the Federal Reserve’s tighter monetary policy to fight 40-year high inflation. In navigating growing economic risks, defensive ETFs like Fidelity MSCI Utilities (FUTY), GraniteShares Gold (BAR), and Consumer Staples Select (XLP)…

Mayor Eric Adams says investigators of a fatal shooting on a New York subway train have few leads

NEW YORK — The Manhattan subway killer who shot a Goldman Sachs researcher at random got away — but not before he was caught on surveillance video, police revealed Monday.

A whale with a lot of money to spend has taken a noticeably bullish stance on Goldman Sachs Group. Looking at options history for Goldman Sachs Group (NYSE:GS) we detected 20 strange trades.